Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria

• Andreas Clemens ,

  * E-mail: andreas.clemens66@gmail.com

  Affiliations Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany, Global Biostatistics and Data Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

  ⨯
• Herbert Noack,

  Affiliation Corporate Division Medicine, Global Therapeutic Area Cardiovascular, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

  ⨯
• Martina Brueckmann,

  Affiliations Corporate Division Medicine, Global Therapeutic Area Cardiovascular, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany

  ⨯
• Gregory Y. H. Lip

  Affiliation University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

  ⨯